May 18, 2017 10:01 AM EDT

#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO

John Carroll

Editor & Founder

Roche has an early-stage T cell bispecific — which binds simultaneously to T cells and tumor cells — called CEA-TCB (RO6958688; RG7802) that it is bullish …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

#AS­CO17 high­lights: Roche ush­ers ear­ly-stage bis­pe­cif­ic in­to view; Agios, Cel­gene un­veil more AG-221 da­ta; Plen­ty more com­ing at AS­CO

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO